ライエル・インミューノファーマのニュース一覧

モルガン・スタンレーはライエル・インミューノファーマ(LYEL.US)のレーティングを中立に据え置き、目標株価を4ドルに据え置いた

モルガン・スタンレーのアナリストVikram Purohitは$Lyell Immunopharma(LYEL.US)$のレーティングを中立に据え置き、目標株価を4ドルに据え置いた。TipRanksのデータによると、このアナリストの最近1年間の的中率は31.1%、平均リターンは-7.1%である。注 TipRanksは、金融アナリストの分析データと、アナリストの的中率および平均リターンに関する情報を

Futuニュース2024/12/24 21:32

Down -30.89% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround

Zacks 2024/12/13 21:40

Lyell Immunopharma Announces Promising Initial Clinical Data for IMPT-314 in Treatment of CAR T-Naïve Patients With Large B-Cell Lymphoma

Barchart2024/12/10 20:26

Reported Earlier, Lyell Releases IMPT-314 Phase 1-2 Results, Highlighting Efficacy And Manageable Safety In B-Cell Lymphoma Treatment At ASH 2024

Benzinga2024/12/10 14:58

Lyell Presents Positive Initial Clinical Data From the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting

GlobeNewswire2024/12/10 10:00

The Analyst Verdict: Lyell Immunopharma In The Eyes Of 4 Experts

Benzinga2024/11/12 20:00

HC Wainwright & Co. Reiterates Neutral on Lyell Immunopharma, Maintains $1 Price Target

Benzinga2024/11/12 19:45

Positive Week for Lyell Immunopharma, Inc. (NASDAQ:LYEL) Institutional Investors Who Lost 26% Over the Past Year

Simply Wall St2024/11/10 21:09

Lyell Immunopharma: Q3 Earnings Snapshot

Yahoo Finance2024/11/08 06:22

Lyell Immunopharma 3Q Loss/Shr $44.6M >LYEL

Dow Jones2024/11/08 05:36

ライエル・インミューノファーマ | 10-Q：Q3 2024 四半期報告書

SEC2024/11/08 05:26

Earnings Flash (LYEL) LYELL IMMUNOPHARMA Posts Q3 Revenue $34,000

MT Newswires2024/11/08 05:19

ライエル・インミューノファーマ | 8-K：ライエル・イムノファーマは、2024年第3四半期の事業ハイライトと財務結果を報告しています

SEC2024/11/08 05:14

Press Release: Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024

Dow Jones2024/11/08 05:05

Lyell Immunopharma Shares Are Trading Higher. The Stock May Be Moving on Continued Strength After the Company Announced Yesterday It Will Present Clinical Data From Its Phase 1-2 Trial of IMPT-314 CAR T-cell Therapy for B-cell Lymphoma at ASH 2024.

Benzinga2024/11/07 01:07

Lyell Announces Presentation of Initial Clinical Data From the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

GlobeNewswire2024/11/05 22:30

Lyell Immunopharma Names Sumant Ramachandra to Board >LYEL

Dow Jones2024/11/01 04:02

Lyell Immunopharma Expects Its Cash Balance Will Fund Ops Into 2027 >LYEL

Dow Jones2024/11/01 04:02

Press Release: Lyell Immunopharma Completes Acquisition of ImmPACT Bio

Dow Jones2024/11/01 04:00

Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy

Benzinga2024/10/31 02:31